Laura Schlicksupp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Schlicksupp has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Ingeborg Dreher
AbbVie Deutschland GmbH & Co. KG, Knollstrasse 50, 67061 Ludwigshafen, Germany
1 shared publication- Mario Richter
Quantitative, Translational and ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
1 shared publication Marta Boysen
AbbVie Deutschland GmbH & Co. KG, Knollstrasse 50, 67061 Ludwigshafen, Germany
1 shared publicationRalf Loebbert
AbbVie Deutschland GmbH & Co. KG, Knollstrasse 50, 67061 Ludwigshafen, Germany
1 shared publication
Latest Publications
- Open Access
- 31 July 2016
- Published by Wiley in Journal of Immunology Research
- Vol. 2016, 1-9
SEC Based Method for Size Determination of Immune Complexes of Therapeutic Antibodies in Animal Matrix
Therapeutic monoclonal antibodies (mAbs) represent a milestone in pharmacological development. Their superiority is based on the combination of high specificity, low toxicity, and long half-life that characterizes biologics. If biologics have Achilles’ heel, it is their potential immunogenicity. To better understand the impact of the size of immune complexes of mAbs on anti-drug antibody (ADA) dependent adverse reactions inMacaca fascicularis, we developed an efficient high-throughput size exclusion chromatography- (SEC-) based methodology that enables analysis of the size, size distribution, and ratio of free and ADA-complexed mAb in serum allowing for assessment of formation and clearance of circulating ADA-mAb immune complexes (CIC).
- 31 July 2016
- Published by Wiley in Journal of Immunology Research
- Vol. 2016, 1-9
Open AccessSEC Based Method for Size Determination of Immune Complexes of Therapeutic Antibodies in Animal Matrix
Therapeutic monoclonal antibodies (mAbs) represent a milestone in pharmacological development. Their superiority is based on the combination of high specificity, low toxicity, and long half-life that characterizes biologics. If biologics have Achilles’ heel, it is their potential immunogenicity. To better understand the impact of the size of immune complexes of mAbs on anti-drug antibody (ADA) dependent adverse reactions inMacaca fascicularis, we developed an efficient high-throughput size exclusion chromatography- (SEC-) based methodology that enables analysis of the size, size distribution, and ratio of free and ADA-complexed mAb in serum allowing for assessment of formation and clearance of circulating ADA-mAb immune complexes (CIC).